Rep. W. Gregory Steube

Preserving Patient Access to Home Infusion Act  This bill specifically includes pharmacy services and home infusion drugs that are administered without a pump as part of covered home infusion therapy under Medicare. The bill also allows nurses and physician assistants to establish and review the plan of care for home infusion therapy, and it specifies that payment may be made regardless of whether a practitioner is physically present in the home at the time the drug is administered.

Maddy summaryHR 2162, the Honey Integrity Act, requires U.S. honey packers to test honey for economically motivated adulteration (EMA) - such as substitution or dilution to increase value - using scientifically validated methods like DNA and NMR testing. Qualifying commercial honey packers (those paying fees to the National Honey Board) must conduct testing, certify compliance, and report results to the FDA within 180 days of the law’s enactment. The bill mandates immediate reporting of EMA findings to authorities and prohibits accepting adulterated honey, with the FDA required to investigate and share data with agencies like Customs and Agriculture. This directly affects honey packers in interstate commerce, aiming to improve product integrity through standardized testing and enforcement.

Maddy summaryThe FOCA Act of 2025 prohibits federal agencies from requiring or banning contractors from using union agreements in construction project bids or contracts. It directly affects federal agencies, contractors, and subcontractors working on federally funded or assisted construction projects (like buildings or infrastructure). The law requires bid documents to not favor or penalize contractors based on whether they have union agreements, aiming to promote open competition and prevent discrimination. This changes how agencies structure bids but does not affect union agreements themselves. The bill applies to all new contracts and subcontracts after enactment, with limited exemptions only for public health/safety emergencies or national security.

Maddy summaryHR 1156, the Pandemic Unemployment Fraud Enforcement Act, extends the time limit for prosecuting fraud related to pandemic unemployment programs. It adds a 10-year window for criminal or civil actions against individuals who falsely claimed benefits under Pandemic Unemployment Assistance (PUA), Federal Pandemic Unemployment Compensation (FPUC), or Mixed Earner Unemployment Compensation (MEUC). The law applies only to fraud committed during these specific pandemic-era programs and does not revive cases where the original statute of limitations had already expired before this bill passed. This change gives authorities more time to pursue fraud cases without altering the programs' core eligibility rules.

Metastatic Breast Cancer Access to Care Act This bill expedites payment of Social Security Disability Insurance (SSDI) benefits and eligibility for Medicare coverage for those with metastatic breast cancer (i.e., breast cancer that has spread to other sites in the body). Specifically, the bill eliminates the 5-month waiting period for SSDI benefits and the subsequent 24-month waiting period for Medicare coverage for individuals with metastatic breast cancer. Under current law, individuals generally must wait 5 months after the onset of disability to begin receiving SSDI benefits and an additional 24 months to become eligible for Medicare.

Maddy summaryHR 2062 would allow taxpayers to deduct membership fees and medical expenses paid through health care sharing ministries (HCSMs) as medical expenses on their federal tax returns, similar to other health costs. It specifically adds HCSM membership to the list of deductible medical expenses under Internal Revenue Code Section 213(d)(1) and clarifies that HCSMs are not treated as health insurance under Section 7702C. This change directly affects individuals enrolled in HCSMs, which are faith-based or community-based cost-sharing groups operating outside traditional insurance. The bill would take effect for tax years beginning after December 31, 2025.

Resident Education Deferred Interest Act or the REDI Act This bill allows borrowers in medical or dental internships or residency programs to defer student loan payments until the completion of their programs.

Maddy summaryHR 2054, the VOTE Act, would prevent states from receiving federal funds for administering federal elections if they provide ballots in any language other than English. It amends the Voting Rights Act by removing current requirements that allow states to provide bilingual ballots in certain areas, eliminating the prohibition on English-only ballots for federal elections. This directly affects states that currently offer ballots in non-English languages to comply with federal language access rules. The bill changes the policy by making federal election funding contingent solely on using English ballots, without requiring multilingual options.

Maddy summaryThe GIFT Act of 2025 prohibits hospitals, critical access hospitals, and rural emergency hospitals from considering a patient's vaccination status when determining organ transplant recipients. This law directly affects organ transplant candidates and healthcare facilities by requiring that recipient selection be based solely on medical criteria, not vaccination history. The bill amends the Social Security Act to add a new provision explicitly banning the use of vaccination status in transplant decisions. This policy change ensures that access to life-saving organ transplants is not influenced by vaccination records.

Maddy summaryHR 1990, the American Innovation and R&D Competitiveness Act of 2025, amends tax rules for businesses to make research and development (R&D) costs more flexible. It allows companies to deduct R&D expenses immediately as business costs (instead of capitalizing them) or to spread these costs over a minimum 60-month period. The bill clarifies which R&D expenses qualify, excludes land improvements and mineral exploration costs, and ensures companies can claim R&D tax credits without conflict with expense treatment. This directly affects businesses that conduct R&D, changing how they account for these costs on tax returns starting for 2022 taxable years.